Biopsy-Driven Neoadjuvant Planning in EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira introduces a second patient case involving a 62-year-old woman with resectable stage IIIA EGFR-mutated non–small cell lung cancer (NSCLC), where the mutation was identified from an initial biopsy. Dr. Spira and Dr. Ticiana Leal discuss how early biomarker identification directly influences multidisciplinary treatment planning, particularly when considering neoadjuvant therapy. Dr. Leal emphasizes that having EGFR mutation results available prior to surgery enables more informed discussions with thoracic surgeons and allows the care team to evaluate whether a neoadjuvant targeted approach may be appropriate. The conversation highlights the importance of integrating molecular data early to guide sequencing decisions and optimize outcomes. Dr. Leal also notes the need to balance potential benefits of preoperative therapy with surgical considerations. This segment underscores how biopsy-driven insights are reshaping treatment strategies in early-stage EGFR-mutated NSCLC.